donor specific antibodies

Biologicalexperimental

Donor-specific antibodies (DSA) are a concept in transplantation medicine and describe the presence of antibodies specific to the Donor's HLA-Molecules. These antibodies can cause antibody-mediated rejection and are therefore considered a contraindication against transplantation in most cases. DSA are a result of B cell and plasma cell activation and bind to HLA and/or non-HLA molecules on the endothelium of the graft. They were first described in 1969 by Patel et al., who found that Transplant recipients who were positively tested for DSA using a complement-dependent cytotoxicity crossmatch assay had a higher risk of transplant rejection. DSA can either be pre-formed or can be formed as a response to the transplantion. — Wikipedia

Clinical trial activity

1 trials · 1 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0

Earliest trial started Mar 9, 2016 (NCT02556879)

Timeline

No events for the selected filters.

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • donor specific antibodies

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT02556879N/AMar 9, 2016University of Paris
Showing 1 of 1 trials
Page 1 / 1

Organizations

Research & Development (1)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
University of ParisAcademic/Hospital1112016
1 organizations
Page 1 / 1